1.EmtinB is currently being developed as a treatment for neurodegenerative dementia and Alzheimer’s disease, and degenerative conditions of the optic nerve. 2.successfully demonstrated that EmtinB passes the blood–brain barrier and is detectable in plasma for up to 24 hours. 3.Preclinical results indicate an increase of up to 800 per cent in repair cell proliferation . 4.Company classed Glaucoma results as unprecented in the injected eye model tests. 5.EmtinB targets a certain key molecule protecting retinal cells which allow messages from the eye to the brain ,the pig study showed the drug was able to reduce damage to the nerve cells and prevent Glaucoma. 6.So now those of you who did not know what the drug EmtinB achieved you know have a few facts on what it actually does,imho will be huge when the market catches on .
NSB Price at posting:
18.0¢ Sentiment: Buy Disclosure: Held
